In summary, the use of needle-free injection technology in intensive insulin therapy for hospitalized patients with T2DM was associated with effective short-term glycemic control, a shorter time to achievement of glycemic targets, and reduced glycemic variability, without an increased risk of hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.